Cargando...
Emerging treatment options for ovarian cancer: focus on rucaparib
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are an exciting class of anticancer drugs, which have revolutionized the management of BRCA mutant/homologous recombination-deficient recurrent high-grade serous ovarian cancer (HGSOC). With three PARPi now approved by the US Food and Drug Admini...
Gardado en:
| Publicado en: | Int J Womens Health |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5735986/ https://ncbi.nlm.nih.gov/pubmed/29290694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S151194 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|